Showing all 6 results
Diclofenac Tablets
FreeProduct Composition & Strength
We supply this product as Enteric Coated (Gastro-Resistant) Tablets or Sustained Release (SR) Tablets.
Active Ingredient Strength (Standard) Formulation Role Diclofenac Sodium USP/BP 25 mg Enteric Coated Pediatric / Mild Pain Diclofenac Sodium USP/BP 50 mg Enteric Coated Standard Acute Dose Diclofenac Sodium USP/BP 75 mg Enteric Coated / SR Intermediate / Injection Switch Diclofenac Sodium USP/BP 100 mg Sustained Release (SR) Once Daily (Chronic Pain) Etoricoxib Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (distinctively colored by strength). The coating masks the bitter taste and ensures stability.
Active Ingredient Strength (Standard) Color (Typical) Primary Indication Etoricoxib USP/BP 60 mg Green Osteoarthritis / Chronic Pain Etoricoxib USP/BP 90 mg White Rheumatoid Arthritis / Dental Pain Etoricoxib USP/BP 120 mg Pale Green Acute Gout (Short Term) Leflunomide Tablets
FreeProduct Composition & Available Portfolio Strengths
We supply Leflunomide across the complete compendial strength matrix, enabling clinicians to manage both rapid initial loading cycles and long-term low-dose maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Leflunomide USP / BP / IP 10 mg Oral Solid Film-Coated Tablet Low-Dose Maintenance: Calibrated for mild-to-moderate maintenance blocks or patients exhibiting sensitive hepatic profiles. Leflunomide USP / BP / IP 20 mg Oral Solid Film-Coated Tablet The Core Commercial Volume: First-line international standard daily maintenance dose for active Rheumatoid and Psoriatic Arthritis. Leflunomide USP / BP / IP 100 mg Oral High-Mass Solid Tablet Initial Loading Regimen: High-potency format utilized exclusively for the rapid 3-day initial tissue saturation phase. Methylprednisolone Tablet
FreeProduct Composition & Available Strengths
We supply Methylprednisolone in a comprehensive, internationally standardized range of strengths to facilitate both low-dose chronic maintenance and the high-dose taper packs mandatory in clinical steroid therapy.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Target Methylprednisolone USP / BP / IP 4 mg Oral Solid Uncoated Tablet (Cross-scored for micro-titration) Baseline Dose / Tapering: For rheumatoid arthritis maintenance and step-down dose regimens. Methylprednisolone USP / BP / IP 8 mg Oral Solid Uncoated Tablet (Cross-scored for micro-titration) Intermediate Management: For moderate asthma exacerbations and chronic dermatological conditions. Methylprednisolone USP / BP / IP 16 mg Oral Solid Uncoated Tablet (Cross-scored for flexible division) High-Potency Control: For acute autoimmune flares, immunosuppression in organ transplants, and oncology support. Paracetamol & Diclofenac Sodium Tablets
FreeProduct Composition & Strength
We supply this product as Enteric Coated or Film Coated Tablets in blister packs.
Active Ingredient Strength (Standard) Role Diclofenac Sodium IP/BP/USP 50 mg Anti-inflammatory / Analgesic Paracetamol IP/BP/USP 500 mg Analgesic / Antipyretic Excipients Q.S. Binder / Disintegrant Prednisolone Tablets
FreePrednisolone Tablets IP 5 mg
Each uncoated tablet contains:
Prednisolone IP 5 mgPrednisolone Tablets IP 10 mg
Each uncoated tablet contains:
Prednisolone IP 10 mgPrednisolone Tablets IP 20 mg
Each uncoated tablet contains:
Prednisolone IP 20 mg
Excipients q.sPrednisolone Tablets IP 10 mg
Each uncoated tablet contains:
Prednisolone IP 10 mg
